文献速递贫血与红细胞疾病

α-地中海贫血对HbSS和HbSC镰状细胞病的多效性影响:降低红细胞阳离子协同转运活性、血清促红细胞生成素和输血负担,但未转化为生存获益

The pleiotropic effects of α-thalassemia on HbSS and HbSC sickle cell disease: Reduced erythrocyte cation co-transport activity, serum erythropoietin, and transfusion burden, do not translate into increased survival.
PubMed 文献 · Am J Hematol · 2022-07-18

该研究基于12年数据,纳入HbSS(n=411)和HbSC(n=146)患者,探讨α-地中海贫血对镰状细胞病的临床和实验室影响。α-地中海贫血显著降低HbSS和HbSC的红细胞KCC活性,并降低HbSS的促红细胞生成素、蛋白尿、血清钾及年化输血负担,但未影响生存。

要点

  • α-地中海贫血显著降低HbSS和HbSC的红细胞KCC活性。
  • α-地中海贫血降低HbSS患者的促红细胞生成素和蛋白尿。
  • α-地中海贫血减少HbSS和HbSC的年化输血负担,但不影响生存。

核心结论

  • α-地中海贫血通过降低红细胞阳离子丢失诱导 milder 表型,但未转化为生存获益。
  • α-地中海贫血降低HbSS和HbSC的输血负担,但不影响年化入院率。
  • HbSS中位生存62年,HbSC中位生存80年,α-地中海贫血对HbSS生存无影响,HbSC中见非显著趋势。

研究设计与样本

  • 研究使用12年数据集,纳入HbSS患者411例和HbSC患者146例,分析α-地中海贫血的临床和实验室关联。
  • 生存分析使用更大 cohort:HbSS 899例,HbSC 240例。

主要发现

  • α-地中海贫血显著降低HbSS(p=0.035)和HbSC(p=0.00045)的红细胞KCC活性。
  • α-地中海贫血增加HbSS血红蛋白(p=0.0009)并降低促红细胞生成素(p=0.0005)。
  • α-地中海贫血降低HbSS蛋白尿(p=0.003),增加血清钠(p=0.0004),降低血清钾(p=5.74×10⁻¹⁰)。
  • α-地中海贫血减少HbSS和HbSC的年化输血负担,但不影响年化入院率。
  • HbSS中位生存62年(n=899),HbSC中位生存80年(n=240);α-地中海贫血不影响HbSS生存,HbSC中见非显著趋势。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

α-Thalassemia is one of the most important genetic modulators of sickle cell disease (SCD). Both beneficial and detrimental effects have been described previously. We use a 12-year data set on a large cohort of patients with HbSS (n = 411) and HbSC (n = 146) to examine a wide range of these clinical and laboratory associations. Our novel findings are that α-thalassemia strongly reduces erythrocyte potassium chloride co-transporter (KCC) activity in both HbSS and HbSC (p = .035 and p = .00045 respectively), suggesting a novel mechanism through which α-thalassemia induces a milder phenotype by reducing red cell cation loss. This may be particularly important in HbSC where reduction in mean cell hemoglobin concentration is not seen and where KCC activity has previously been found to correlate with disease severity. Additionally, we show that α-thalassemia not only increases hemoglobin in patients with HbSS (p = .0009) but also reduces erythropoietin values (p = .0005), demonstrating a measurable response to improved tissue oxygenation. We confirm the reno-protective effect of α-thalassemia in patients with HbSS, with reduced proteinuria (p = .003) and demonstrate a novel association with increased serum sodium (p = .0004) and reduced serum potassium values (p = 5.74 × 10-10 ). We found patients with α-thalassemia had a reduced annualized transfusion burden in both HbSS and HbSC, but α-thalassemia had no impact on annualized admission rates in either group. Finally, in a larger cohort, we report a median survival of 62 years in patients with HbSS (n = 899) and 80 years in those with HbSC (n = 240). α-thalassemia did not influence survival in HbSS, but a nonsignificant trend was seen in those with HbSC.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Brewin JN, Nardo-Marino A, Stuart-Smith S, et al. The pleiotropic effects of α-thalassemia on HbSS and HbSC sickle cell disease: Reduced erythrocyte cation co-transport activity, serum erythropoietin, and transfusion burden, do not translate into increased survival. Am J Hematol. 2022. PMID: 35802781. doi:10.1002/ajh.26652

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。